Johnson & Johnson will not pursue obesity drugs based on GLP-1 mechanisms, Chief Executive Officer Joaquin Duato said during an interview at the Economic Club of Washington, DC. Duato told interviewer David Rubenstein that the company intends to concentrate its efforts on cancer and neuroscience rather than entering the rapidly developing obesity-treatment market.
Duato made the point directly: "We are not going to be in the GLP-1 area." He framed oncology and neuroscience as domains where Johnson & Johnson can deliver greater impact and where the company will focus its research and investment priorities.
On the oncology front, Duato stated a clear ambition: Johnson & Johnson aims to be the number one cancer company globally by 2030. The company already holds leading positions in treatments for multiple myeloma and markets therapies for lung cancer. As part of its cancer strategy, J&J completed a cash purchase of Halda Therapeutics in 2025 for $3.05 billion to obtain a new oral prostate cancer therapy.
Neuroscience is another priority. Duato identified dementia as a major healthcare challenge and emphasized ongoing commitments to research in neurodegenerative diseases. He acknowledged that the company has faced prior setbacks in this area but said J&J continues to invest in efforts to address those conditions.
Beyond therapeutic focus, Duato highlighted the potential role of artificial intelligence across Johnson & Johnson's business lines. He said AI could accelerate drug discovery and enhance medical-device capabilities, calling out robotic surgery as an area where improvements are possible. "We are just at the beginning," he said, describing the company as in the early stages of a growth cycle driven by pharmaceuticals and medical devices.
The remarks come after a period of corporate reshaping: Johnson & Johnson has spun off its consumer-health unit, Kenvue, and separated its orthopedics division. The company reported a total shareholder return of 47% in 2025, a figure Duato and management can point to as they pursue their strategic priorities.
Duato noted that competitors are pursuing obesity treatments following successful weight-loss drugs from other manufacturers, and said J&J's choice to stay out of the GLP-1 obesity area is a deliberate strategic decision rather than a default position.
As the company channels resources into oncology, neuroscience and emerging AI-enabled capabilities, management will face the task of translating those priorities into research progress, commercial launches and device innovation while monitoring competitive developments in adjacent therapeutic areas.